Company intelligence / Profile preview

Affinimark Technologies

New Haven, Connecticut, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Affinimark Technologies received FDA Breakthrough Device Designation in October 2019 for its diagnostic test strip that provides real-time, on-the-spot detection of cerebrospinal fluid (CSF) leaks[5]. The proprietary test strip works similarly to a pregnancy test, yielding immediate positive or negative results to enable rapid clinical diagnosis[2].

Therapeutic areas: Neurology
Modalities: Device
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Affinimark Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affinimark Technologies.

Explore the full profile